title: A multicenter comparison of isradipine and felodipine in the treatment of mild-to-moderate hypertension. The Physician's Study Group.
abstract: The objective of this study was to compare the tolerability of isradipine and felodipine in patients with mild-to-moderate hypertension. Following a 4-week placebo run-in, 143 patients entered a 12-week double-blind multicenter study. Patients were randomized to receive either isradipine (n = 72) or felodipine (n = 71) at a dose of 2.5 mg twice daily. Dose-doubling and the addition of enalapril (2.5 mg once daily) was permitted if diastolic blood pressure (DBP) was > 90 mm Hg at weeks 4 and 8, respectively. Isradipine reduced blood pressure from 165/104 +/- 13/6 mm Hg at baseline to 144/88 +/- 13/8 mm Hg at week 12 (P < .001) whereas felodipine reduced blood pressure from 171/104 +/- 17/6 mm Hg at baseline to 150/92 +/- 19/9 mm Hg at week 12 (P < .001). Similar incidences of headache, flushing, dizziness and tachycardia were reported in both groups. However, the incidence of ankle edema was significantly lower in the isradipine group (14% v 30%) (P = .028). It is concluded that isradipine represents a practical improvement over felodipine in the treatment of hypertension.
authors: Clinical Research Department Sandoz Australia, North Ryde, New South Wales.
authors: S A
authors: SA
authors: Cutler
authors: J J
authors: JJ
authors: Hammond
mesh_terms: D000328:Adult; D000842:Ankle; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004487:Edema / Q000139:chemically induced; D004656:Enalapril / Q000627:therapeutic use; D015736:Felodipine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017275:Isradipine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D004656:Enalapril; D015736:Felodipine; D017275:Isradipine